The Stickler Syndrome encompasses several genetic diseases, which cause various eye disorders and are difficult to diagnose. For this reason, the objective of this research is to identify all the genes involved in these pathologies in order to improve the process of diagnosis and treatment.
Principal: Dr Esther Pomares
IMO Foundation's own funds
July 2019 - present
The Stickler Syndrome (STL) comprises a group of rare genetic diseases that affect the conjunctive tissue, characterized by the variable association of ocular manifestations (such as myopia, cataracts, retinal detachment or hereditary vitreoretinopathy), orofacial anomalies, osteoarticular affectations and deafness of variable severity. This pathology has an estimated population incidence ranging between 1:7500 and 1:9000 in neonates, and represents the most common hereditary cause of juvenile retinal detachment. At the genetic level, STL is caused by pathogenic variants in one of the genes responsible for the synthesis of collagens 2, 9 and 11, and in most families it is transmitted following an autosomal dominant inheritance pattern. However, recent studies have identified new genes associated with recessive forms of STL, which show the high genetic heterogeneity of this type of pathologies and open the door to the identification of possible new STL genes.
Despite the efforts to standardize the symptomatological criteria of STL, its clinical diagnosis remains a very demanding challenge, given the wide variability of phenotypic expression. In addition, other collagen diseases present very similar clinical manifestations, such as Wagner, Marshall or Donnai-Barrow syndromes. In this context, the identification of the genetic cause is crucial to confirm the specific pathology with certainty. Therefore, this project aims to identify and characterize new genes and novel genetic variants responsible for STL and other related syndromes, by studying those families with clinical pictures compatible with this type of pathologies. This analysis will be carried out using next generation sequencing, which will make it possible to determine the molecular cause, either in known genes or in genes not yet associated with STL.